scholarly journals Genetic variation of clock genes and cancer risk: a field synopsis and meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (14) ◽  
pp. 23978-23995 ◽  
Author(s):  
Clara Benna ◽  
Charlotte Helfrich-Förster ◽  
Senthilkumar Rajendran ◽  
Halenya Monticelli ◽  
Pierluigi Pilati ◽  
...  
Keyword(s):  
Genetic Variation ◽  
Cancer Risk ◽  
Clock Genes ◽  
Meta Analysis

scholarly journals Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls

2012 ◽  
Vol 21 (22) ◽  
pp. 4980-4995 ◽  
Author(s):  
Maria N. Timofeeva ◽  
Rayjean J. Hung ◽  
Thorunn Rafnar ◽  
David C. Christiani ◽  
John K. Field ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Genetic Variation ◽  
Cancer Risk ◽  
Lung Cancer Risk ◽  
Meta Analysis ◽  
Common Genetic Variation

scholarly journals Genetic variation and gastric cancer risk: a field synopsis and meta-analysis

Gut ◽  
2015 ◽  
Vol 64 (8) ◽  
pp. 1209-1219 ◽  
Author(s):  
Simone Mocellin ◽  
Daunia Verdi ◽  
Karen A Pooley ◽  
Donato Nitti
Keyword(s):  
Gastric Cancer ◽  
Genetic Variation ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Gastric Cancer Risk

scholarly journals Implications for Prostate Cancer of Insulin-Like Growth Factor-I (IGF-I) Genetic Variation and Circulating IGF-I Levels

2007 ◽  
Vol 92 (12) ◽  
pp. 4820-4826 ◽  
Author(s):  
Mattias Johansson ◽  
James D. McKay ◽  
Fredrik Wiklund ◽  
Sabina Rinaldi ◽  
Martijn Verheus ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Genetic Variation ◽  
Cancer Risk ◽  
Association Studies ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
Increased Risk ◽  
Igf I ◽  
Circulating Levels ◽  
I Gene

Abstract Background: Elevated levels of circulating IGF-I have consistently been associated with increased prostate cancer risk. We recently found a haplotype in the 3′ region of the IGF-I gene associated with increased risk of prostate cancer, and we hypothesized that the observed association is mediated by circulating IGF-I. Materials and Methods: We analyzed haplotypes and three haplotype-tagging single nucleotide polymorphisms (htSNPs) in the 3′ region of the IGF-I gene in relation to circulating levels IGF-I in 698 control subjects from the CAncer Prostate in Sweden (CAPS) study and 575 cases and controls from the prospective Northern Sweden Health and Disease Cohort (NSHDC) study. We also performed a meta-analysis of these two and four other association studies on genetic variation in the 3′ region of the IGF-I gene in relation to circulating IGF-I levels. Results: The IGF-I haplotype previously associated with prostate cancer risk, labeled “TCC,” was associated with elevated levels of IGF-I in the CAPS study (P = 0.02), but not in the NSHDC study. In contrast, two of the three IGF-I htSNPs tagging this haplotype, rs6220 and rs7136446, were associated with elevated levels of IGF-I in the NSHDC (P = 0.03 and P = 0.04, respectively), but not in the CAPS study. In the meta-analysis, the TCC haplotype and the rs6220 SNP were associated with elevated levels of circulating IGF-I (P = 0.001 and P < 0.0001, respectively). Conclusions: Genetic variation in the 3′ region of the IGF-I gene seems to influence circulating levels of IGF-I. This observation is consistent with the hypothesis that variation in the IGF-I gene plays a role in prostate cancer susceptibility by influencing circulating levels of IGF-I.

scholarly journals Associations between female lung cancer risk and sex steroid hormones: a systematic review and meta-analysis of the worldwide epidemiological evidence on endogenous and exogenous sex steroid hormones

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Hui Zeng ◽  
Zhuoyu Yang ◽  
Jiang Li ◽  
Yan Wen ◽  
Zheng Wu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Risk ◽  
Steroid Hormones ◽  
Lung Cancer Risk ◽  
Meta Analysis ◽  
Sex Steroid Hormones ◽  
Sex Steroid ◽  
Sex Steroid Hormone ◽  
Hormone Exposure ◽  
Female Lung Cancer

Abstract Background Published findings suggest sex differences in lung cancer risk and a potential role for sex steroid hormones. Our aim was to perform a meta-analysis to investigate the effects of sex steroid hormone exposure specifically on the risk of lung cancer in women. Methods The PubMed, MEDLINE, Web of Science, and EMBASE databases were searched. The pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) for female lung cancer risk associated with sex steroid hormones were calculated overall and by study design, publication year, population, and smoking status. Sensitivity analysis, publication bias, and subgroup analysis were performed. Results Forty-eight studies published between 1987 and 2019 were included in the study with a total of 31,592 female lung cancer cases and 1,416,320 subjects without lung cancer. Overall, higher levels of sex steroid hormones, both endogenous (OR: 0.92, 95% CI: 0.87–0.98) and exogenous (OR: 0.86, 95% CI: 0.80–0.93), significantly decreased the risk of female lung cancer by 10% (OR: 0.90, 95% CI: 0.86–0.95). The risk of lung cancer decreased more significantly with a higher level of sex steroid hormones in non-smoking women (OR: 0.88, 95% CI: 0.78–0.99) than in smoking women (OR: 0.98, 95% CI: 0.77–1.03), especially in Asia women (OR: 0.84, 95% CI: 0.74–0.96). Conclusions Our meta-analysis reveals an association between higher levels of sex steroid hormone exposure and the decreased risk of female lung cancer. Surveillance of sex steroid hormones might be used for identifying populations at high risk for lung cancer, especially among non-smoking women.

Sign in / Sign up

Export Citation Format

Share Document